Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Reumatología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Reclutando
Fase 3
ClinicalTrials.gov
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
INTERVENTIONAL
Inicio: 21 de nov de 2024
ID: NCT06617325
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment
INTERVENTIONAL
Inicio: 15 de jul de 2021
ID: NCT04908189
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-blind, Study to Assess Efficacy and Safety of Ianalumab (VAY736) Versus Placebo in Warm Autoimmune Hemolytic Anemia (wAIHA) Patients Who Failed at Least One Line of Treatment
INTERVENTIONAL
Inicio: 30 de dic de 2022
ID: NCT05648968
Completado
Fase 3
ClinicalTrials.gov
(OSKIRA-1): A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate
INTERVENTIONAL
Inicio: 1 de sept de 2010
ID: NCT01197521
Terminado
Fase 3
ClinicalTrials.gov
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
INTERVENTIONAL
Inicio: 5 de jun de 2019
ID: NCT03970837
Completado
Fase 2
ClinicalTrials.gov
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Superiority of CRx-102 Over Each of Its Components When Given to Subjects With Active Rheumatoid Arthritis (RA)
INTERVENTIONAL
Inicio: 1 de oct de 2007
ID: NCT00551707
Terminado
Fase 2
ClinicalTrials.gov
A Randomised, Double Blind, Placebo-controlled, Multiple Dose, Phase 2b, 24 Week Trial Followed by an Open Label Extension of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
INTERVENTIONAL
Inicio: 30 de oct de 2012
ID: NCT01636843
Completado
Fase 2
ClinicalTrials.gov
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Obinutuzumab in Patients With ISN/RPS 2003 Class III or IV Lupus Nephritis
INTERVENTIONAL
Inicio: 13 de nov de 2015
ID: NCT02550652
Completado
Fase 3
ClinicalTrials.gov
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate for Inducing and Sustaining Clinical Response in the Treatment of DMARD-Naïve Adults With Early Active Rheumatoid Arthritis
INTERVENTIONAL
Inicio: 1 de ene de 2012
ID: NCT01519791
Terminado
Fase 2
ClinicalTrials.gov
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants With Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
INTERVENTIONAL
Inicio: 14 de ene de 2022
ID: NCT05097989
Terminado
Fase 3
ClinicalTrials.gov
(OSKIRA-X): A Long-term Extension Study to Assess the Safety and Efficacy of Fostamatinib Disodium in the Treatment of Rheumatoid Arthritis
INTERVENTIONAL
Inicio: 1 de ene de 2011
ID: NCT01242514
Completado
Fase 4
ClinicalTrials.gov
A Multicenter, 2 Part Study to Assess the Efficacy and Safety of Acthar Gel in Subjects With Rheumatoid Arthritis With Persistently Active Disease Despite Dual-DMARD Treatment
INTERVENTIONAL
Inicio: 7 de nov de 2016
ID: NCT02919761
Completado
Fase 2
ClinicalTrials.gov
A Phase 2b Study to Evaluate the Efficacy and Safety of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis
INTERVENTIONAL
Inicio: 1 de ago de 2012
ID: NCT01706926
Completado
Fase 3
ClinicalTrials.gov
A 1-Year Safety Study of Duloxetine in Patients With Fibromyalgia Syndrome
INTERVENTIONAL
Inicio: 1 de jul de 2005
ID: NCT00125892
Reclutando
Fase 1
ClinicalTrials.gov
A Phase 1, First-time-in-human, Three-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK4527363 in Healthy Participants (Part A), Participants With Active Systemic Lupus Erythematosus (Part B), Healthy Participants of Chinese and Japanese Descent (Part C) and Participants With Interstitial Lung Disease Associated With Connective Tissue Disease (Part D)
INTERVENTIONAL
Inicio: 2 de sept de 2024
ID: NCT06576271
Activo, no recluta
Fase 2
ClinicalTrials.gov
A Randomized, Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL Pre-filled Syringe With 1 mL Pre-filled Syringe in Adult Participants With Autoimmune Disease
INTERVENTIONAL
Inicio: 2 de jul de 2024
ID: NCT06293365
Completado
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults With Active Psoriatic Arthritis
INTERVENTIONAL
Inicio: 17 de jun de 2013
ID: NCT01860976
Completado
Fase 2
ClinicalTrials.gov
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
INTERVENTIONAL
Inicio: 13 de nov de 2014
ID: NCT02265744
Terminado
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Double-dummy, Active Controlled Study of Canakinumab (ACZ885) on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/ or Colchicine Are Contraindicated, Not Tolerated or Ineffective
INTERVENTIONAL
Inicio: 20 de jun de 2011
ID: NCT01362608
Completado
Fase 3
ClinicalTrials.gov
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
INTERVENTIONAL
Inicio: 30 de sept de 2013
ID: NCT01892436
Anterior
1
...
6
7
8
...
434
Siguiente
Filtros